GeneFirst wins second major Innovate UK competitive grant to improve cancer treatment using its ATOM-seq™ NGS technology
Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a 12-month grant of £457,000 from Innovate UK’s Open Programme Round 3 to continue development of DNA sequencing technology to improve cancer treatment through better detection of cancer mutations in blood.
Innovate UK’s Open R&D Funding programme provides businesses with grants to develop game-changing or disruptive ideas. ATOM-seq™ technology received initial feasibility funding from Innovate UK earlier in the year. The Round 3 grant will allow GeneFirst to further clinically validate the ATOM-seq™ technology, through the commencement of clinical evaluation and patient trials at key oncology centres across the UK.
About GeneFirst Limited
GeneFirst Limited is a molecular diagnostics company delivering proprietary NGS and PCR technologies and products in the fields of cancer diagnostics, infectious disease and personalised medicine. GeneFirst offers robust easy-to-use, sensitive, and affordable products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe, effective and affordable medicines.
For more information please contact:
Chief Operations Officer
+44 (0) 1865 407 098
+44 (0) 1865 407 400